Elting LS, Rubenstein EB, Martin CG, Kurtin Danna, Rodriguez S, Laiho E, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol J Am Soc Clin Oncol. 2001;19:1137–46.
Google ScholarÂ
Estcourt L, Stanworth S, Doree C, Hopewell S, Trivella M, Murphy M. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012;CD004269.
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncol Williston Park N. 2015;29:282–94.
Degliuomini MD, Armstrong K, Mauguen A, Slotkin EK, Roberts SS, Dunkel IJ, et al. Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention. Pediatr Blood Cancer. 2022;69:e29776.
Google ScholarÂ
Goodnough LT, DiPersio JFD. Issues in the management of cancer-related thrombocytopenia. Oncol Williston Park N. 2002;16:1558–67. discussion 1570, 1572–4.
Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D, et al. Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clin Breast Cancer. 2018;18:380–6.
Google ScholarÂ
Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer J Multinatl Assoc Support Care Cancer. 2020;28:925–32.
Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93:203–10.
Google ScholarÂ
Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer. 2011;11:131.
Google ScholarÂ
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98:10–23.
Google ScholarÂ
Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol. 2019;37:2892–8.
Google ScholarÂ
Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer J Multinatl Assoc Support Care Cancer. 2014;22:1217–22.
Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021;106:1148–57.
Google ScholarÂ
Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103:e169–72.
Google ScholarÂ
Miao J, Leblebjian H, Scullion B, Parnes A. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. Am J Hematol. 2018;93:E86–8.
Google ScholarÂ
Soff G, Leader A, Al-Samkari H, Falanga A, Maraveyas A, Sanfilippo K, et al. Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy. J Thromb Haemost JTH. 2024;22:53–60.
Google ScholarÂ
Guidelines Detail. NCCN. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1493 (accessed Jan 21, 2025).
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2017;15:1520–41.
Google ScholarÂ
CTEP Home Page – NCI. 2025; published online June 25. https://dctd.cancer.gov/programs/ctep (accessed Aug 13, 2025).
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.
Google ScholarÂ
Soff GA, Al-Samkari H, Leader A, Eisen M, Saad H. Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. Cancer Med. 2024;13:e7429.
Google ScholarÂ
Adly AAM, Ragab IA, Ismail EAR, Farahat MM. Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia. Platelets. 2015;26:645–50.
Google ScholarÂ
Bride KL, Lim D, Paessler M, Lambert MP. Can Immature Platelet Fraction (IPF) be Used to Assess Bleeding Risk in Pediatric Immune Thrombocytopenia (ITP) and to Differentiate ITP from Bone Marrow Failure/Aplastic Anemia? A Retrospective Analysis. Blood. 2015;126:3474.
Google ScholarÂ
Lee YK, Jeon K, Kim M, Jiwon L, Jee-Soo L, Han-Sung K, et al. Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery. Blood. 2018;132:128.
Google ScholarÂ
Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol. 2014;166:592–600.
Google ScholarÂ
Al-Samkari H. Optimal Management of Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists. Blood Rev. 2024;63:101139.
Google ScholarÂ
Soff GA, Ray-Coquard I, Rivera LJM, Fryzek J, Mullins M, Bylsma LC, et al. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia. PloS One. 2022;17:e0257673.
Google ScholarÂ
Amgen. RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer. clinicaltrials.gov, 2022 https://clinicaltrials.gov/ct2/show/NCT03362177 (accessed Nov 7, 2022).
Amgen. A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer. clinicaltrials.gov, 2022 https://clinicaltrials.gov/ct2/show/NCT03937154 (accessed Nov 7, 2022).
